News
VKTX
67.58
+4.08%
2.65
Viking Therapeutics Q1 2024 Earnings Preview
Viking Therapeutics, Inc. Is scheduled to announce its Q1 earnings results on Wednesday, April 24th. The consensus EPS Estimate is -$0.28. Over the last 3 months, analysts have revised down their estimates for the company's earnings.
Seeking Alpha · 18h ago
Brian Big Idea On Technical Analysis
NASDAQ · 18h ago
3 Potential Biopharma Buyout Targets
Recent lack of M&A activity and rising interest rates have led to a 20% decline in small-cap biotech equities. Big Pharma's surplus of cash and key patent expirations should lead to increased M& a volume in the coming year. Three promising small biopharma names are attractive as standalone entities but would make logical buyout targets. Mirum Pharmaceuticals, Inc., ImmunoGen, Inc. And GLP-1 are three names that could be attractive.
Seeking Alpha · 22h ago
Baron Health Care Fund Q1 2024 Shareholder Letter
Baron Health Care Fund advanced 8.92% in the quarter ended March 31, 2024. The Fund's performance was in line with the Russell 3000 Health Care Index and the S&P 500 Index. Investments in health care equipment, pharmaceuticals, and life sciences added the most value in the period.
Seeking Alpha · 1d ago
Weekly Report: what happened at VKTX last week (0415-0419)?
Weekly Report · 2d ago
13 new obesity drugs could hit the market by 2029 amid surging demand
13 new obesity drugs could hit the market by 2029 amid surging demand for the products in the U.S. World Health Organization predicts 50% of US adults will be considered obese by 2030. Sales of weight-loss drugs have soared, with Novo Nordisk and Eli Lilly generating $9.7B in 2023.
Seeking Alpha · 2d ago
Hepion ends Phase 2 study for NASH drug due to cash restraints
Seeking Alpha · 4d ago
Noteworthy Friday Option Activity: WST, ATGE, VKTX
NASDAQ · 4d ago
Viking (VKTX) to Report Q1 Earnings: What's in the Cards?
NASDAQ · 5d ago
Surprising Analyst 12-Month Target For VB
NASDAQ · 5d ago
Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead
Seeking Alpha · 5d ago
Weight-loss drug developer Metsera raises $290 million in funding
Weight-loss drug developer Metsera raises $290 million in funding. The company is developing injectable and oral drugs to treat obesity. Multiple drug companies are competing to grab a slice of the weight-loss market. The market is estimated to reach $100 billion by the end of the decade.
Reuters · 6d ago
LLY, VKTX, or NOVO: Which Weight-Loss Drugmaker Could Gain the Best Returns?
TipRanks · 04/17 03:10
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Viking Therapeutics has outperformed the market over the past 5 years by 38.64% on an annualized basis. The company has a market capitalization of $7.38 billion. If an investor bought $100 of VKTX stock 5 years ago, it would be worth $759.07 today.
Benzinga · 04/15 20:30
Pfizer Eyeing Viking Therapeutics? A Scenario Among All The M&A Talk
Recent trial data from Viking Therapeutics could make it a potential acquisition target for Pfizer. The GLP-1 weight loss market is projected to grow to $100 billion by 2030. Novo Nordisk and Eli Lilly are the leaders in the space. Pfizer makes logical sense in a potential deal for Viking. The company recently completed a successful Phase 2 trial of its drug in the obesity treatment.
Seeking Alpha · 04/15 20:08
Weekly Report: what happened at VKTX last week (0408-0412)?
Weekly Report · 04/15 10:24
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
NASDAQ · 04/10 21:45
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
MarketWatch · 04/10 13:27
Novo Nordisk: The Moat Won't Last Forever
Novo Nordisk A/S has more than doubled since late 2022. The GLP-1 market is projected to grow to $100 billion by 2030. Novo Nordisk is the preeminent player in the weight loss space. The company faces stiffening competition from Eli Lilly and Company and new entrants on the horizon.
Seeking Alpha · 04/09 15:30
ClearBridge Small Cap Growth Strategy Q2 2024 Portfolio Manager Commentary
Seeking Alpha · 04/09 15:00
More
Webull provides a variety of real-time VKTX stock news. You can receive the latest news about Viking Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.